The following is a list of clinical trials with which the Section of Rheumatology at Dartmouth-Hitchcock Medical Center is currently involved. Talk to your doctor to find out if a clinical trial is right for you.
Rheumatology Clinical Trials
A Long-Term, Open-Label Extension Study Of Tofacitinib (Cp-690,550) For The Treatment Of Psoriatic Arthritis (A3921092)
A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis (Amgen Protocol Number (Etanercept) #20130207)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis
A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to MTX
A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)
A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 with Rituximab in Subjects with Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment
A Randomized, Head-to-Head, Single-Blinded Study to Assess Changes in the Immune Profile in Response to Treatment with Subcutaneous Abatacept in Combination with Methotrexate versus Subcutaneous Adalimumab in Combination with Methotrexate in Adults with Early Rheumatoid Arthritis who are Naive to Biologic Disease-Modifying Antirheumatic Drugs
Adenocorticotrophic Hormone for Acute Treatment of Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate.
Biomarkers in Rheumatic Diseases
Validation of VISTA, a Negative Regulator as a Novel Therapy for Autoimmune Disease